Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2026-05-12 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 93% confidence The document is titled “Delårsrapport Q1 2026” and contains comprehensive financial key figures for Q1 (jan–mar 2026 vs 2025), a CEO commentary (“VD-ord”), business overview, pipeline updates, and details on capital increases after the period. It is an actual quarterly interim report (“delårsrapport”), not merely an announcement or presentation. Therefore it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-12 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Interim Report Q1 2026 (January–March)” and contains detailed Q1 financial results (operating result, EPS, cash flow, liquid assets), narrative CEO statement, corporate overview, pipeline updates, and executive commentary. It is the actual interim/quarterly report itself, not a brief notice or presentation. Therefore it falls under the Interim/Quarterly Report category. Q1 2026
2026-05-12 English
Kommuniké från årsstämma den 4 maj 2026 i Ascelia Pharma AB
Regulatory Filings
2026-05-04 Swedish
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026
Regulatory Filings
2026-05-04 English
Change in Number of Shares and Votes in Ascelia Pharma AB
Share Issue/Capital Change Classification · 95% confidence The document is a press release dated 30 April 2026, announcing a change in the number of shares and votes in Ascelia Pharma AB due to a directed new issue of ordinary shares. It provides updated share and voting figures but does not contain detailed financial statements, management discussion, or comprehensive financial data. The document length is 1686 characters, which is short and typical for an announcement rather than a full report. It explicitly states the change in share capital structure, which aligns with announcements about share issues or capital changes. Therefore, this document fits the category of Share Issue/Capital Change (SHA).
2026-04-30 English
Ändring av antalet aktier och röster i Ascelia Pharma AB
Share Issue/Capital Change Classification · 100% confidence The document is a press release dated April 30, 2026, announcing a change in the number of shares and voting rights in Ascelia Pharma AB due to a directed new share issue. It provides specific updated share counts and voting rights but does not contain financial statements or detailed financial analysis. The document is short (1773 characters) and focuses on capital structure changes resulting from a share issuance. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or other filing types. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2026-04-30 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.